Lupin Ltd: History, Latest Updates, Milestones, Subsidiaries, and Share Price
INTRODUCTION
Lupin Ltd is one of India’s leading pharmaceutical companies, known for its innovation-driven approach and global presence. Founded in 1968, the company has grown its global footprint to more than 100 countries, emphasizing its strengths in generics, biosimilars, and specialty pharmaceuticals. It has built a reputation in key therapeutic areas such as cardiovascular, respiratory, and central nervous system treatments. Recently, the Lupin share price has garnered investor interest, driven by the company’s regulatory achievements and strategic growth initiatives. This article delves into Lupin’s history, key milestones, subsidiaries, recent developments, and share price performance.
Lupin Ltd moves in 2025:
- Lupin strengthened its presence in the U.S. generics space by launching Ipratropium Bromide Nasal Solution in 0.03% and 0.06% strengths, further diversifying its respiratory care offerings.
- The company received USFDA approvals for its Liraglutide and Glucagon Injectable Products, manufactured at its Nagpur injectable facility, marking a key milestone in its complex generics pipeline.
- In July 2025, Lupin’s manufacturing facilities at Pithampur Unit-2 and Unit-3 underwent successful inspections by the USFDA, marking a key regulatory milestone. Both sites received Form-483s with limited observations, reflecting Lupin’s proactive regulatory compliance efforts.
- Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary, was granted GMP certification by Australia's Therapeutic Goods Administration (TGA) for its API facility in Dabhasa, Gujarat, enhancing its global CDMO credibility.
- These strategic regulatory and product developments are expected to boost operational efficiency and investor confidence, potentially driving upward momentum in the lupin share price.
Evolution of Lupin Ltd: From Past to Present:
Past:
Founded in 1968 by Desh Bandhu Gupta with just Rs. 5,000, Lupin began by supplying iron and folic acid tablets to government health programs. A significant breakthrough for Lupin was its advancement in anti-TB medications, establishing the company as the world’s leading producer of tuberculosis drugs. Over the years, Lupin expanded into generics, APIs, and branded formulations, with strategic global acquisitions like Gavis Pharmaceuticals (U.S.) and Medisol (France), establishing its presence across over 100 countries.
Present:
In 2025, Lupin stands as a leading global pharma player with strong growth metrics. Its FY25 revenue grew 13.5% YoY, and profit surged nearly 70%. With focused investments in complex generics, biosimilars, and injectables, especially in the U.S. market, Lupin has significantly improved margins and ROCE (21.6%). Strong quarterly results have also boosted investor confidence, positively impacting the Lupin share price.
| Name | Lupin Limited |
| Founded year | 1968 |
| Key People | Vinita D. Gupta -CEO and Nilesh Gupta-MD. |
| Subsidiaries | Lupin Pharmaceuticals, Inc., Novel Laboratories, Inc.,Polynova Industries Limited, Medquímica Indústria Farmacêutica S.A., Lupin Holdings BV and many more… |
| Headquarters | Mumbai, Maharashtra, India |
| Sector | Pharmaceuticals |
| Nse code | LUPIN |
| Bse code | 500257 |
Timeline of Lupin Ltd :
| Year | Milestone |
| 1972 | Set up first formulations plant and R&D center in Aurangabad, India. |
| 1979 | Commissioned a new formulations plant. |
| 1981 | Began production of Ethambutol, expanding its portfolio. |
| 1987 | Opened Cephalexin plant in Mandideep and 7 ADCA plants in Ankleshwar. |
| 1988 | Established Lupin Human Welfare and Research Foundation (LHWRF). |
| 1989 | Received USFDA approvals for Ankleshwar and Mandideep plants; formed Lupin Chemicals (Thailand) Ltd. |
| 1991 | Started injectable Cephalosporin production at Mandideep. |
| 1992 | Set up fermentation plant at Tarapur and sterile plant at Mandideep. |
| 1993 | Launched IPOs for Lupin Laboratories Ltd. and Lupin Chemicals Ltd. |
| 1997 | Approved 7 ACCA plants at Ankleshwar and Rifampicin plant at Tarapur. |
| 1999 | Received UK MCA approval for Mandideep Cephalosporin plant. |
| 2000 | Achieved USFDA approval. |
| 2001 | Became the only Asian company to get USFDA approval for sterile Cephalosporin; rebranded as Lupin Ltd. |
| 2002 | Crossed 100 patent filings. |
| 2003 | Formed Lupin Pharmaceuticals Inc. in the U.S. |
| 2004 | Launched Suprax® in the U.S., entering branded space. |
| 2006 | Raised FCCBs; Goa facility received USFDA & MHRA approval; issued bonus shares. |
| 2007 | Started Jammu facility; acquired Rubamin Labs (Novodigm Ltd.) and Kyowa Pharma, Japan. |
| 2008 | Acquired Hormosan Pharma GmbH, Germany; set up biotech facility in Pune. |
| 2009 | Acquired majority stake in Multi-Care Pharma, Philippines. |
| 2010 | Became 5th largest generic player in the U.S. |
| 2011 | Partnered with Medicis; acquired Goanna® brand and I’rom Pharma, Japan; opened Pithampur facility. |
| 2012 | Included in NIFTY 50 Index. |
| 2013 | Acquired exclusive U.S. rights for Alinia® oral suspension. |
| 2014 | Entered Latin America via Grin, Mexico; acquired Nanomi B.V. for complex injectables. |
| 2015 | Opened Center of Excellence in Florida. |
| 2016 | Started Japan plant; acquired Shionogi & Co. and Gavis Pharma. |
| 2017 | Acquired Symbiomix; launched Softovac®; opened Sikkim facility. |
| 2019 | Partnered with Boehringer Ingelheim for MEK inhibitor; divested Kyowa Pharma. |
| 2020 | Launched gProAir (Albuterol Sulphate) inhaler. |
| 2023 | Launched first inhalation product in Germany. |
| 2024 | Received tentative USFDA approval for Emtricitabine + Tenofovir Alafenamide; to be produced at Nagpur. |
Inside Lupin Ltd:
Lupin Ltd
Corporate actions: Lupin Ltd. has announced 24 dividend payouts since July 15, 2003, highlighting its commitment to consistent shareholder returns. Over the past 12 months alone, the company declared an equity dividend of Rs. 12.00 per share. Based on the current Lupin share price of Rs. 1,982.90, this translates to a dividend yield of 0.61%, reflecting a stable return for long-term investors.
Main News:
- July 24, 2025 – Lupin received USFDA approval for its Liraglutide Injection (bioequivalent to Victoza) and Glucagon for Injection. These products will be produced at its Nagpur injectables facility and target a combined U.S. market worth over $458 million.
- July 18, 2025 – The USFDA inspection at Pithampur Unit-2 concluded with four Form-483 observations. The inspection was conducted from July 8 to July 17.
- July 18, 2025 – Lupin’s subsidiary Lupin Manufacturing Solutions received GMP certification from Australia’s TGA for its API plant in Dabhasa, Gujarat.
- July 18, 2025 – Another USFDA inspection at Pithampur Unit-3 concluded with three Form-483 observations, conducted between July 7 to July 17.
- July 4, 2025 – Lupin launched its Ipratropium Bromide Nasal Spray in the U.S., bioequivalent to Atrovent Nasal Spray, targeting allergic rhinitis and related respiratory conditions.
Current Lupin share price NSE:
| COMPANY NAME | SECTOR | SHARE PRICE LINK |
| Lupin Ltd | Pharmaceuticals & Drugs | Lupin share price |
Achievements and Milestones:
Below is a snapshot of Lupin’s recent awards and recognitions, highlighting its excellence in innovation, sustainability, employee welfare, and healthcare impact.
| Year | Award / Recognition | Awarded By / Event |
| 2025 | Green Manufacturing Competitors Award (Tarapur Team) | Futurescaper |
| 2025 | Champions for Excellence in Transfer Pricing | UBS Forums – Tax Strategy & Planning Summit |
| 2025 | Top-Rated Company | AmbitionBox Employee Choice Awards (ABECA) |
| 2025 | Medal of Honor for Environmental Protection (Mandideep Facility) | Annual Environment Awards – MP Govt |
| 2025 | Gold Award – Vovilup Brand | ACEF Global Customer Engagement Summit |
| 2025 | Golden Award for Payroll Automation Implementation | factoHR |
| 2025 | Best Social Welfare Initiative of the Year | UBS Forums – CSR Summit |
| 2025 | Sustainable Organization of the Year | Net Zero Summit – UBS Forums |
| 2025 | Best Impact Creator in Healthcare – LupinLife | Big Impact Awards – Big FM 92.7 |
| 2024 | Patient-Centric Pharma Company of the Year – Humrahi Program | IHW Patient First Awards |
| 2024 | Patient-Centric Diagnostic Laboratories Company of the Year – Diagnostics Team | IHW Patient First Awards |
| 2024 | Two Accolades – CII National Challenger Awards (Pithampur Team) | CII |
| 2024 | Commendation for Quality Culture | National Board for Quality Promotion, QCI |
CONCLUSION
Lupin Ltd’s journey from a modest pharmaceutical startup in 1968 to a global healthcare leader today reflects its relentless commitment to innovation, quality, and global expansion. With consistent regulatory milestones, diversified global operations, and a growing portfolio in complex generics and biosimilars, the company continues to capture market attention. Investor sentiment is further reinforced by the steadily rising Lupin share price, supported by robust financials and forward-looking strategies. As Lupin moves ahead, it remains a key player shaping the future of healthcare—both in India and globally.
To check the lupin share price today and explore detailed stock analysis, visit Enrich Money. It also offers a free demat account with zero annual maintenance charges, making it one of the best stock trading apps for beginners in India.
Frequently Asked Questions:
Where can I find real-time updates on the Lupin share price?
Check the latest Lupin share price and live stock updates on Enrich Money’s stock here.
How has the Lupin share price moved over the past 52 weeks?
The Lupin share price hit a 52-week high of Rs. 2,402.90 and a low of Rs. 1,795.20, showing strong movement in the Lupin share price over the year.
What influences the Lupin share price the most?
The Lupin Laboratories share price is influenced by factors such as USFDA approvals, global market expansion, financial performance, and developments in generics and biosimilars.
How has the Lupin share price performed recently?
The Lupin share price has seen positive momentum in 2025, driven by strong quarterly results, regulatory approvals, and increased investor confidence in its specialty drug portfolio.
Is the Lupin share price suitable for long-term investment?
Many investors view the Lupin share price as a solid long-term investment due to the company’s focus on innovation and steady global growth.
What recent developments have contributed to the rise in Lupin Limited share price?
The rise in the Lupin Limited share price is linked to recent USFDA approvals, the launch of new respiratory and diabetes drugs, and improved operational margins in FY25.
Check our ORCA app to analyze stocks' performance:
- Lupin Limited share price
- Lupin Ltd Technical Analysis
- Lupin Ltd Future Price
- Lupin Ltd Financial Statements
- Lupin Ltd Shareholding Pattern
- Lupin Ltd share latest news
- Lupin Ltd Stock/Company Overview
Related Stocks
Disclaimer: This blog is dedicated exclusively for educational purposes. Please note that the securities and investments mentioned here are provided for informative purposes only and should not be construed as recommendations. Kindly ensure thorough research prior to making any investment decisions. Participation in the securities market carries inherent risks, and it's important to carefully review all associated documents before committing to investments. Please be aware that the attainment of investment objectives is not guaranteed. It's important to note that the past performance of securities and instruments does not reliably predict future performance.
